Peptide LibraryEptifibatide
Eptifibatide is an FDA-approved glycoprotein IIb in the Platelet Glycoprotein Inhibitor class. Eptifibatide contains a KGD sequence modelled on the RGD motif that fibrinogen uses to engage platelet glycoprotein IIb/IIIa. By occupying that receptor reversibly it prevents fibrinogen and von Willebrand factor cross-linking of platelets, blocking the final common step of platelet aggregation.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 832 g/mol
- Half-life
- About 2.5 hours (plasma elimination half-life)
- FDA status
- Approved
- Evidence level
- FDA Approved
- Human dose established
- Yes
- Administration Route
- Intravenous
- Frequency
- Intravenous bolus followed by continuous infusion
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Research summary
Cyclic heptapeptide platelet aggregation inhibitor approved for acute coronary syndrome and for patients undergoing percutaneous coronary intervention.
Research evidence
- Regulatory review (FDA label)2 reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Eptifibatide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Eptifibatide dosage evidence
Eptifibatide has an FDA-approved human dosage as a hospital intravenous treatment for acute coronary syndrome and for patients undergoing percutaneous coronary intervention (PCI). The label gives a 180 mcg/kg intravenous bolus followed by a continuous infusion of 2 mcg/kg/min, with a second 180 mcg/kg bolus 10 minutes after the first for PCI, and reduces the infusion to 1 mcg/kg/min when creatinine clearance is below 50 mL/min.
| Human dosing established | Yes |
|---|---|
| Route | Intravenous |
| Frequency | Intravenous bolus followed by continuous infusion |
| Duration studied | Acute coronary syndrome: up to 72 hours. PCI: until hospital discharge or up to 18–24 hours, with at least 12 hours recommended |
| Half-life | About 2.5 hours (plasma elimination half-life) |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — acute coronary syndrome (unstable angina or NSTEMI)FDA-approved label · FDA prescribing information | Adults with acute coronary syndrome managed medically or with PCI | 180 mcg/kg bolus as soon as possible after diagnosis, then 2 mcg/kg/min; 1 mcg/kg/min if creatinine clearance is below 50 mL/min | Intravenous | Bolus, then continuous infusion | Until hospital discharge or the start of bypass surgery, up to 72 hours | Indicated to decrease the rate of a combined endpoint of death or new myocardial infarction | Eptifibatide injection (Slate Run Pharmaceuticals) — FDA prescribing information, DailyMed |
| FDA label — percutaneous coronary intervention, including stentingFDA-approved label · FDA prescribing information | Adults undergoing PCI | 180 mcg/kg bolus immediately before PCI, then 2 mcg/kg/min, with a second 180 mcg/kg bolus 10 minutes after the first; infusion 1 mcg/kg/min if creatinine clearance is below 50 mL/min | Intravenous | Two boluses, then continuous infusion | Until hospital discharge or up to 18–24 hours, whichever comes first; at least 12 hours recommended | Indicated to decrease the rate of a combined endpoint of death, new myocardial infarction or need for urgent intervention | Eptifibatide injection (Slate Run Pharmaceuticals) — FDA prescribing information, DailyMed |
Where sources disagree
- Eptifibatide is a platelet aggregation inhibitor given in hospital, together with aspirin and heparin as the label sets out. The label warns that it can cause serious bleeding and acute, profound thrombocytopenia; bleeding and low blood pressure are its most common adverse reactions.
- The label contraindicates it in people with recent bleeding or a bleeding disorder, severe uncontrolled hypertension, major surgery within 6 weeks, stroke within 30 days or any hemorrhagic stroke, another intravenous GP IIb/IIIa inhibitor, or dependence on renal dialysis.
- The original brand, Integrilin, is no longer listed on DailyMed; the label cited here is an FDA-approved generic eptifibatide injection label. Safety and effectiveness in children have not been studied, according to the label.
Sequence & molecular data
| Molecular formula | C35H49N11O9S2 |
|---|---|
| Molecular weight | 832 g/mol |
| PubChem CID | 448812 |
| FDA UNII | NA8320J834 |
| ChEMBL | CHEMBL1174 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Eptifibatide contains a KGD sequence modelled on the RGD motif that fibrinogen uses to engage platelet glycoprotein IIb/IIIa. By occupying that receptor reversibly it prevents fibrinogen and von Willebrand factor cross-linking of platelets, blocking the final common step of platelet aggregation. Its short half-life means platelet function recovers within hours of stopping the infusion.
Studies
- Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial
- Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
- Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy
- Eptifibatide-Induced Thrombocytopenia--When Inhibitor Turns Killer
- Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study)
Research statistics
1,134 PubMed publications · 50.6% human clinical research · 30 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Eptifibatide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
How FDA approval, compounding and research-only status differ
Benefits
—
Eptifibatide side effects
No side effects listed yet for this entry.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Eptifibatide: frequently asked questions
What is Eptifibatide?
Cyclic heptapeptide platelet aggregation inhibitor approved for acute coronary syndrome and for patients undergoing percutaneous coronary intervention.
How does Eptifibatide work?
Eptifibatide contains a KGD sequence modelled on the RGD motif that fibrinogen uses to engage platelet glycoprotein IIb/IIIa. By occupying that receptor reversibly it prevents fibrinogen and von Willebrand factor cross-linking of platelets, blocking the final common step of platelet aggregation.
Is Eptifibatide FDA approved?
Yes. Eptifibatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Eptifibatide?
Compounds most often compared with Eptifibatide include Angiotensin II, Cetrorelix, Corticorelin and Cosyntropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial — Neurology, 2025External reference
- Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke — N Engl J Med, 2024External reference
- Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy — Circulation, 2004External reference
- Eptifibatide-Induced Thrombocytopenia--When Inhibitor Turns Killer — Am J Ther, 2016External reference
- Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study) — Am J Cardiol, 2005External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Eptifibatide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Eptifibatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →